Market Overview:
The global proprotein convertase subtilisin/kexin type 9 (PCSK9) market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. In addition, technological advancements in the field of PCSK9 inhibitors are also contributing to the growth of this market. However, patent expiries and stringent regulatory approvals are restraining the growth of this market. Based on type, SX-PCK9 held a major share of the global proprotein convertase subtilisin/kexin type 9 (PCSK9) market in 2017. This segment is expected to maintain its dominance during the forecast period owing to its high efficacy and safety profile as compared to other types such as O-304 and K-312. By application, cardiovascular disease was observed as one of the most lucrative segments for PCSK9 inhibitors in 2017 owing to rising incidences rates across all geographies coupled with increasing awareness about preventive measures for heart diseases among people worldwide.
Product Definition:
Protein convertase subtilisin/kexin type 9 (PCSK9) is a serine protease that inactivates the low-density lipoprotein receptor (LDLR). PCSK9 is produced by the liver and circulates in the blood. It binds to LDLR on hepatocytes, leading to its degradation. Inhibition of PCSK9 increases LDLR levels on hepatocytes, which leads to an increase in plasma levels of LDL cholesterol and a decrease in risk for cardiovascular disease.
SX-PCK9:
SX-PCK9, also known as Proprotein Convertase Subtilisin/Kexin Type 9 is a protein-based enzyme that acts as a protease. It has been observed to be the most active out of all the other subtilisin enzymes. The biological role of this product is to digest proteins and peptide bonds in case of cancer cells or during heart attacks.
O-304:
O-304 is a form of hexafluorozirconic acid that is used as an intermediate during the manufacturing process of Proprotein Convertase Subtilisin/Kexin Type 9 (PCS9). O-304 has been characterized as non-toxic and exhibits no known side effects in humans. The product also shows excellent stability towards pH and temperature, making it suitable for use in PCS9 production.
Application Insights:
Metabolic syndrome is the fastest growing application segment owing to the increasing prevalence of obesity and diabetes. Proprotein convertase subtilisin/kexin type 9 finds applications in metabolic syndrome treatment as it reduces oxidative stress on cells, improves insulin sensitivity, and decreases inflammation. These factors are likely to increase product demand in the coming years.
The other factor contributing towards segment growth includes liver disease which has been surging among all age groups across regions including Asia Pacific, North America, Europe & Middle East & Africa due largely to various causes such as alcohol consumption and drug abuse among others.
Regional Analysis:
North America dominated the global market in 2017. The region is expected to maintain its position during the forecast period due to increasing prevalence of cardiovascular diseases, liver disease, and metabolic syndrome. Moreover, local presence of key players such as Pfizer Inc.; Merck & Co., Inc.; and Sanofi are also contributing towards regional growth.
Asia Pacific is anticipated to be the fastest-growing region over the forecast period owing to rising healthcare expenditure by governments along with an increase in awareness regarding novel treatment options for HCV infection coupled with a rise in disposable income levels among people living in this region. Furthermore, growing penetration of generic drugs due to patent expirations or regulatory changes will also support regional growth during the estimated time span from 2018 - 2030 (Ref).
Latin America has been experiencing high economic development over recent years which has resulted into increased healthcare spending by governments on account of rising incidence rates associated with infectious diseases such as HCV infection (Ref).
Growth Factors:
- Increasing prevalence of obesity and metabolic syndrome
- Growing awareness about the benefits of PCSK9 inhibitors for managing cholesterol levels
- Rising demand for novel therapies to treat cardiovascular diseases
- Technological advancements in the field of PCSK9 inhibitors development
- increasing number of clinical studies evaluating the safety and efficacy of PCSK9 inhibitors
Scope Of The Report
Report Attributes
Report Details
Report Title
Proprotein Convertase Subtilisin/Kexin Type 9 Market Research Report
By Type
SX-PCK9, O-304, K-312, BLSM-201, DCRPCSK-9, Others
By Application
Cardiovascular Disease, Homozugous Familial Hyperchalesterolemia, Liver Disease, Metabolic Syndrome, Others
By Companies
AFFiRiS AG, Betagenon AB, Bioleaders Corp, BioLingus AG, Catabasis Pharmaceuticals Inc, Dicerna Pharmaceuticals Inc, Eli Lilly and Co, Ensemble Therapeutics Corp, Kowa Co Ltd, Novartis AG, Pfizer Inc, Regeneron Pharmaceuticals Inc, Serometrix LLC, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd, The Medicines Company
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
122
Number of Tables & Figures
86
Customization Available
Yes, the report can be customized as per your need.
Global Proprotein Convertase Subtilisin/Kexin Type 9 Market Report Segments:
The global Proprotein Convertase Subtilisin/Kexin Type 9 market is segmented on the basis of:
Types
SX-PCK9, O-304, K-312, BLSM-201, DCRPCSK-9, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Cardiovascular Disease, Homozugous Familial Hyperchalesterolemia, Liver Disease, Metabolic Syndrome, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- AFFiRiS AG
- Betagenon AB
- Bioleaders Corp
- BioLingus AG
- Catabasis Pharmaceuticals Inc
- Dicerna Pharmaceuticals Inc
- Eli Lilly and Co
- Ensemble Therapeutics Corp
- Kowa Co Ltd
- Novartis AG
- Pfizer Inc
- Regeneron Pharmaceuticals Inc
- Serometrix LLC
- Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
- The Medicines Company
Highlights of The Proprotein Convertase Subtilisin/Kexin Type 9 Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- SX-PCK9
- O-304
- K-312
- BLSM-201
- DCRPCSK-9
- Others
- By Application:
- Cardiovascular Disease
- Homozugous Familial Hyperchalesterolemia
- Liver Disease
- Metabolic Syndrome
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Proprotein Convertase Subtilisin/Kexin Type 9 Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Proprotein Convertase Subtilisin/Kexin Type 9 is a pro-enzyme that helps to break down proteins.
Some of the key players operating in the proprotein convertase subtilisin/kexin type 9 market are AFFiRiS AG, Betagenon AB, Bioleaders Corp, BioLingus AG, Catabasis Pharmaceuticals Inc, Dicerna Pharmaceuticals Inc, Eli Lilly and Co, Ensemble Therapeutics Corp, Kowa Co Ltd, Novartis AG, Pfizer Inc, Regeneron Pharmaceuticals Inc, Serometrix LLC, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd, The Medicines Company.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Proprotein Convertase Subtilisin/Kexin Type 9 Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Proprotein Convertase Subtilisin/Kexin Type 9 Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Proprotein Convertase Subtilisin/Kexin Type 9 Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Proprotein Convertase Subtilisin/Kexin Type 9 Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Proprotein Convertase Subtilisin/Kexin Type 9 Market Size & Forecast, 2020-2028
4.5.1 Proprotein Convertase Subtilisin/Kexin Type 9 Market Size and Y-o-Y Growth
4.5.2 Proprotein Convertase Subtilisin/Kexin Type 9 Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 SX-PCK9
5.2.2 O-304
5.2.3 K-312
5.2.4 BLSM-201
5.2.5 DCRPCSK-9
5.2.6 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Cardiovascular Disease
6.2.2 Homozugous Familial Hyperchalesterolemia
6.2.3 Liver Disease
6.2.4 Metabolic Syndrome
6.2.5 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Proprotein Convertase Subtilisin/Kexin Type 9 Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Proprotein Convertase Subtilisin/Kexin Type 9 Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 SX-PCK9
9.6.2 O-304
9.6.3 K-312
9.6.4 BLSM-201
9.6.5 DCRPCSK-9
9.6.6 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Cardiovascular Disease
9.10.2 Homozugous Familial Hyperchalesterolemia
9.10.3 Liver Disease
9.10.4 Metabolic Syndrome
9.10.5 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 SX-PCK9
10.6.2 O-304
10.6.3 K-312
10.6.4 BLSM-201
10.6.5 DCRPCSK-9
10.6.6 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Cardiovascular Disease
10.10.2 Homozugous Familial Hyperchalesterolemia
10.10.3 Liver Disease
10.10.4 Metabolic Syndrome
10.10.5 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 SX-PCK9
11.6.2 O-304
11.6.3 K-312
11.6.4 BLSM-201
11.6.5 DCRPCSK-9
11.6.6 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Cardiovascular Disease
11.10.2 Homozugous Familial Hyperchalesterolemia
11.10.3 Liver Disease
11.10.4 Metabolic Syndrome
11.10.5 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 SX-PCK9
12.6.2 O-304
12.6.3 K-312
12.6.4 BLSM-201
12.6.5 DCRPCSK-9
12.6.6 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Cardiovascular Disease
12.10.2 Homozugous Familial Hyperchalesterolemia
12.10.3 Liver Disease
12.10.4 Metabolic Syndrome
12.10.5 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 SX-PCK9
13.6.2 O-304
13.6.3 K-312
13.6.4 BLSM-201
13.6.5 DCRPCSK-9
13.6.6 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Cardiovascular Disease
13.10.2 Homozugous Familial Hyperchalesterolemia
13.10.3 Liver Disease
13.10.4 Metabolic Syndrome
13.10.5 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Proprotein Convertase Subtilisin/Kexin Type 9 Market: Competitive Dashboard
14.2 Global Proprotein Convertase Subtilisin/Kexin Type 9 Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 AFFiRiS AG
14.3.2 Betagenon AB
14.3.3 Bioleaders Corp
14.3.4 BioLingus AG
14.3.5 Catabasis Pharmaceuticals Inc
14.3.6 Dicerna Pharmaceuticals Inc
14.3.7 Eli Lilly and Co
14.3.8 Ensemble Therapeutics Corp
14.3.9 Kowa Co Ltd
14.3.10 Novartis AG
14.3.11 Pfizer Inc
14.3.12 Regeneron Pharmaceuticals Inc
14.3.13 Serometrix LLC
14.3.14 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
14.3.15 The Medicines Company
